Answers are grounded in this paper and cite their sources.
Prospective cohort study demonstrates real-life walking speed detects disease progression earlier in primary progressive multiple sclerosis, indicating higher sensitivity than standard metrics.
Background: Primary progressive multiple sclerosis (PPMS) involves gradual disability accumulation driven by neurodegeneration. Standard outcomes, including the Expanded Disability Status Scale (EDSS) and timed 25-foot walk (T25FW), lack sensitivity to subtle functional changes. Real-life walking speed (RWS) measured with wearable sensors may offer a more responsive marker of progression. Objectives: In a prospective cohort (2012–2022) at the University Medical Center Hamburg-Eppendorf, adults with PPMS (18–65 years, EDSS ⩽7.0) underwent repeated EDSS, T25FW, Nine-Hole Peg Test (9HPT), and Symbol Digit Modalities Test (SDMT). RWS was recorded using an accelerometer. Disease progression was defined as ⩾20% worsening in T25FW/9HPT, ⩾8-point SDMT decline, EDSS increase (⩾1.0 or ⩾0.5 if >5), or RWS reduction >0.08 m/s. Results: Among 110 participants (mean age: 52 years; baseline EDSS: 3.5) followed for a median of 3 years, RWS showed a symmetric distribution and declined steadily with increasing EDSS, unlike the skewed T25FW distribution. Annual progression was detected in >30% of participants using RWS, compared with <20% for EDSS/SDMT and <10% for T25FW/9HPT. Composite endpoints including RWS identified earlier and more frequent disease progression ( p < 0.01). Conclusion: Continuous RWS monitoring is more sensitive than conventional metrics for detecting functional decline in PPMS and may strengthen progression endpoints.
No takes yet. Share an insight, caveat, or question.
Cotinat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: